China’s Vaccine Congress Draws Pharmaceutical MNCs
This article was originally published in PharmAsia News
Executive Summary
More than 300 scientists and executives from pharmaceutical MNCs congregated at the recent First World Vaccine Congress held in Guangdong, China. Participants included top officials from the International Vaccine Institute of Korea, Baxter International, Intercell and GSK, reflecting overseas companies' optimism in the country's vaccine market. The event aimed to boost the internationalization of China's vaccine industry, speeding up changes in its production and biotechnology. Although major vaccine player Baxter has not started its vaccine business in China, it has been keeping a close eye on the country and analysts believe it will enter the market soon. Baxter considers China a high-priority international market, especially for vaccine products. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.